European Archives - Page 600 of 1304 - European Medical Journal

Taking women to the top of pharma

Pharma is a popular destination for women entering the workforce, but how can the lack of representation at senior levels be addressed?

How can pharma companies create successful ERGs?

For pharma, building an ERG can be essential for inclusivity. Find out how to create a great one with these top tips.

IL-17 and -23 Inhibitors for the Treatment of Psoriasis

Psoriasis is a chronic inflammatory skin disorder affecting approximately 60 million people worldwide. The condition presents with rapid hyperproliferation and dysregulated differentiation of epidermal keratinocytes, manifesting clinically as salmon pink plaques with overlying silvery-white scale.

Season finale: a sneak peek at the new issue of GOLD

To mark the final episode of Season 4, Isabel and Jade reminisce about their favourite moments from the series and give an exclusive teaser for the next issue of GOLD magazine.

Kite Pharma’s Christi Shaw on the story behind her drive

Christi Shaw, former CEO, Kite Pharma, shares her thoughts on improving access to cell therapies and her motivations for working in oncology

Pharma in the US

Exploring the current state of the US pharmaceutical market, this article investigates the balance between innovation and access to care in the country.

It Takes Guts to Treat Gastrointestinal Disorders

Alex Ford joins Jonathan on this episode of the EMJ Podcast to discuss disorders of gut–brain interaction and gastrointestinal disorders

My journey with diversity, equity and inclusion

Roche’s Davidek Herron offers his thoughts on the state of diversity, equity and inclusion in the pharma industry.

Addressing the Impacts of Sex and Gender on Respiratory Care

Chronic lung disease currently accounts for a large percentage of deaths in both males and females. This podcast challenges stereotypes and provides insights into the differences in respiratory care between sexes.

Mapping a path to personalised medicine

Despite continued advances in personalised medicine, there is still more to be done to encourage policy makers and payers to back these life-changing initiatives.